Comera Life Sciences Holdings, Inc.
CMRAOTCHealthcare● Active
$0.00
+$0.00(+9900.00%)
Market Cap$3074
P/E Ratio—
52W High$0.0002
52W Low$0.0001
Comera Life Sciences Holdings, Inc. (CMRA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CMRA · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 9, 2023EPS Actual
-$0.10
Revenue
$0.00B
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 9, 2023
After Market Close
CMRA reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 9, 2023 | — | -$0.10 | — | $0.00B | — | — |
| — Q3 FY2023 | Aug 10, 2023 | — | -$0.08 | — | $0.00B | — | — |
| — Q2 FY2023 | May 11, 2023 | — | -$0.13 | — | $0.00B | — | — |
| — Q1 FY2023 | Mar 16, 2023 | — | -$0.18 | — | $0.00B | — | — |
| — Q4 FY2022 | Nov 10, 2022 | — | -$0.20 | — | $0.00B | — | — |
| — Q3 FY2022 | Aug 10, 2022 | — | -$1.74 | — | $0.00B | — | — |
| — Q1 FY2022 | Mar 31, 2022 | — | -$0.17 | — | $0.00B | — | — |
| — Q4 FY2021 | Dec 31, 2021 | — | -$0.07 | — | $0.00B | — | — |
Q4 FY2023
Nov 9, 2023
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2023
Aug 10, 2023
EPS Actual
-$0.08
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
May 11, 2023
EPS Actual
-$0.13
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2023
Mar 16, 2023
EPS Actual
-$0.18
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2022
Nov 10, 2022
EPS Actual
-$0.20
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2022
Aug 10, 2022
EPS Actual
-$1.74
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2022
Mar 31, 2022
EPS Actual
-$0.17
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2021
Dec 31, 2021
EPS Actual
-$0.07
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 9, 2023 | — | $0.35 | $0.32 | -9.88% |
| — Q3 FY2023 | Aug 10, 2023 | — | $0.62 | $0.64 | +2.41% |
| — Q2 FY2023 | May 11, 2023 | — | $0.73 | $0.73 | +0.00% |
| — Q1 FY2023 | Mar 16, 2023 | — | $1.12 | $1.13 | +0.89% |
| — Q4 FY2022 | Nov 10, 2022 | — | $1.21 | $1.41 | +16.53% |
| — Q3 FY2022 | Aug 10, 2022 | — | $2.77 | $2.85 | +2.89% |
| — Q1 FY2022 | Mar 31, 2022 | — | $10.20 | $10.20 | +0.00% |
| — Q4 FY2021 | Dec 31, 2021 | — | $10.13 | $10.13 | +0.00% |
Q4 FY2023-9.88%
Report Date
Nov 9, 2023
EPS Beat/Miss
—
Price Before
$0.35
Price After
$0.32
Q3 FY2023+2.41%
Report Date
Aug 10, 2023
EPS Beat/Miss
—
Price Before
$0.62
Price After
$0.64
Q2 FY2023+0.00%
Report Date
May 11, 2023
EPS Beat/Miss
—
Price Before
$0.73
Price After
$0.73
Q1 FY2023+0.89%
Report Date
Mar 16, 2023
EPS Beat/Miss
—
Price Before
$1.12
Price After
$1.13
Q4 FY2022+16.53%
Report Date
Nov 10, 2022
EPS Beat/Miss
—
Price Before
$1.21
Price After
$1.41
Q3 FY2022+2.89%
Report Date
Aug 10, 2022
EPS Beat/Miss
—
Price Before
$2.77
Price After
$2.85
Q1 FY2022+0.00%
Report Date
Mar 31, 2022
EPS Beat/Miss
—
Price Before
$10.20
Price After
$10.20
Q4 FY2021+0.00%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$10.13
Price After
$10.13
Beat Rate0 / 8 quarters
Largest Move+16.53% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CMRA ends December
Comera Life Sciences Holdings, Inc. (CMRA) most recently reported earnings on November 9, 2023 for Q4 FY2023, posting EPS of $-0.10 (in line with the analyst consensus of —). The next CMRA earnings date is expected around September 1, 2026.
Each quarter, investors track CMRA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CMRA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CMRA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CMRA earnings · 4 questionsComera Life Sciences Holdings, Inc.'s next earnings report is expected around September 1, 2026. CMRA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CMRA historically reports after market close (AMC).
CMRA earnings datewhen is CMRA earningsCMRA next earnings datewhen does CMRA report earningsCMRA earnings calendar
▸ Source: FMP · Comera Life Sciences Holdings, Inc. SEC filings · US GAAP · Comera Life Sciences Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026